Nimbus Discovery and Proteros Enter into X-Ray Crystallography Agreement
News Nov 09, 2012
Nimbus Discovery LLC, announced that it has executed a Privileged Partnership Agreement with Proteros Biostructures GmbH, Martinsried, Germany.
Nimbus joins a select number of prestigious pharmaceutical and biotechnology companies that have entered into Privileged Partnership Agreements with Proteros. Privileged Partners are able to preferentially access Proteros' new Gallery Structures, technologies and extensive in-house expertise to accelerate structure-based drug discovery efforts.
Jonathan Montagu, Vice President, Business Development and Operations at Nimbus commented, "Our cutting-edge computational platform relies heavily upon high quality x-ray structure data. Hence, our current collaboration with Proteros has been instrumental in our success with previously inaccessible targets. This expanded partnership is a logical progression of how we are integrating leading edge technologies to create a new model for drug discovery."
Cony D'Cruz, Chief Business Officer and President, Proteros, US Inc. added, "We are excited to expand our collaboration with Nimbus. The relationship has been very productive and we look forward to continuing to support Nimbus' innovative and proven discovery platform."
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE